Status:
COMPLETED
Oral Nadolol for the Treatment of Adults With Mild Asthma
Lead Sponsor:
Invion, Inc.
Collaborating Sponsors:
University of Houston
Sandler Program for Asthma Research
Conditions:
Asthma
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to confirm previous observations in asthmatics that chronic nadolol treatment reduces asthmatic airway hyper-responsiveness.
Eligibility Criteria
Inclusion
- Pre-bronchodilator FEV1 80% or greater than the predicted value.
- PC20 FEV1 ≤4 mg/ml on methacholine challenge test.
- Blood Pressure ≥ 100/65mm Hg.
- Pulse rate ≥ 60 beats/min.
- No significant health issues.
- Non-smoker or X-smoker \< 10 pack/year.
Exclusion
- History of upper/lower respiratory tract infection or asthma exacerbation within 6 weeks of first baseline visit.
- Currently diagnosed with chronic obstructive pulmonary disease (COPD).
- Used any oral or inhaled corticosteroids within 4 weeks of the first baseline visit.
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00670267
Start Date
January 1 2007
End Date
June 1 2009
Last Update
May 11 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Baylor College of Medicine
Houston, Texas, United States, 77030